Terms: = Skin cancer AND HOXD13, SPD, 3239, P35453, HOX4I
26 results:
1. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
2. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.
Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
[TBL] [Abstract] [Full Text] [Related]
3. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract] [Full Text] [Related]
4. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death.
Bresler SC; Gosnell HL; Ko JS; Angeles CV; Ronen S; Billings SD; Patel RM
Am J Surg Pathol; 2023 Dec; 47(12):1417-1424. PubMed ID: 37727934
[TBL] [Abstract] [Full Text] [Related]
5. Combined Radiomodifying Effect of Fucoidan from the Brown Alga
Malyarenko OS; Malyarenko TV; Usoltseva RV; Kicha AA; Ivanchina NV; Ermakova SP
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979354
[TBL] [Abstract] [Full Text] [Related]
6. Large, linear pigmentation anomaly: an unusual dyspigmentation case.
Vander Does A; Motosko C; Yosipovitch G
Dermatol Online J; 2022 Dec; 28(6):. PubMed ID: 36809100
[TBL] [Abstract] [Full Text] [Related]
7. Rescuing cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear spd-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract] [Full Text] [Related]
8. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract] [Full Text] [Related]
10. Effect of aromatherapy on cancer complications: A systematic review.
Farahani MA; Afsargharehbagh R; Marandi F; Moradi M; Hashemi SM; Moghadam MP; Balouchi A
Complement Ther Med; 2019 Dec; 47():102169. PubMed ID: 31779991
[TBL] [Abstract] [Full Text] [Related]
11. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract] [Full Text] [Related]
12. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.
Pellegrini C; Botta F; Massi D; Martorelli C; Facchetti F; Gandini S; Maisonneuve P; Avril MF; Demenais F; Bressac-de Paillerets B; Hoiom V; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Marrett L; Zanetti R; Dwyer T; Thomas NE; Begg CB; Berwick M; Puig S; Potrony M; Nagore E; Ghiorzo P; Menin C; Manganoni AM; Rodolfo M; Brugnara S; Passoni E; Sekulovic LK; Baldini F; Guida G; Stratigos A; Ozdemir F; Ayala F; Fernandez-de-Misa R; Quaglino P; Ribas G; Romanini A; Migliano E; Stanganelli I; Kanetsky PA; Pizzichetta MA; García-Borrón JC; Nan H; Landi MT; Little J; Newton-Bishop J; Sera F; Fargnoli MC; Raimondi S; ; ;
Lancet Child Adolesc Health; 2019 May; 3(5):332-342. PubMed ID: 30872112
[TBL] [Abstract] [Full Text] [Related]
13. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Cubillos-Zapata C; Martínez-García MÁ; Campos-Rodríguez F; Sánchez de la Torre M; Nagore E; Martorell-Calatayud A; Hernández Blasco L; Chiner Vives E; Abad-Capa J; Montserrat JM; Cabriada-Nuño V; Cano-Pumarega I; Corral-Peñafiel J; Diaz-Cambriles T; Mediano O; Somoza-González M; Dalmau-Arias J; Almendros I; Farré R; López-Collazo E; Gozal D; García-Río F;
Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30487198
[TBL] [Abstract] [Full Text] [Related]
14. The RNA-binding Protein MEX3B Mediates Resistance to cancer Immunotherapy by Downregulating HLA-A Expression.
Huang L; Malu S; McKenzie JA; Andrews MC; Talukder AH; Tieu T; Karpinets T; Haymaker C; Forget MA; Williams LJ; Wang Z; Mbofung RM; Wang ZQ; Davis RE; Lo RS; Wargo JA; Davies MA; Bernatchez C; Heffernan T; Amaria RN; Korkut A; Peng W; Roszik J; Lizée G; Woodman SE; Hwu P
Clin Cancer Res; 2018 Jul; 24(14):3366-3376. PubMed ID: 29496759
[No Abstract] [Full Text] [Related]
15. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract] [Full Text] [Related]
16. Squamous cell carcinoma arising from chronic sacrococcygeal pilonidal disease: a case report.
Michalopoulos N; Sapalidis K; Laskou S; Triantafyllou E; Raptou G; Kesisoglou I
World J Surg Oncol; 2017 Mar; 15(1):65. PubMed ID: 28302173
[TBL] [Abstract] [Full Text] [Related]
17. [Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Shao L; Hong W; Zheng L; He C; Zhang B; Xie F; Song Z; Lou G; Zhang Y
Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):391-400. PubMed ID: 24854556
[TBL] [Abstract] [Full Text] [Related]
18. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract] [Full Text] [Related]
19. Cost effectiveness of Mohs micrographic surgery: review of the literature.
Tierney EP; Hanke CW
J Drugs Dermatol; 2009 Oct; 8(10):914-22. PubMed ID: 19852120
[TBL] [Abstract] [Full Text] [Related]
20. Incidence and familial risks in pituitary adenoma and associated tumors.
Hemminki K; Försti A; Ji J
Endocr Relat Cancer; 2007 Mar; 14(1):103-9. PubMed ID: 17395979
[TBL] [Abstract] [Full Text] [Related]
[Next]
